Recent Updates
Recently added Catalysts

SKY0402

Phase 3

Bunion | Small molecule | Other |Pacira BioSciences, Inc.|Last Updated: Aug 5, 2013

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDDMCBiomarker
Total Trials1
Total Enrollment193
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00890682Study of Postoperative Analgesia in BunionectomyPHASE3 COMPLETED 193Apr 1, 2009Nov 1, 2009Aug 5, 20131 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Area Under the Curve (AUC) of the Numeric Rating Scale at Rest (NRS-R) Pain Intensity Scores
0-24 hours

The AUC of the NRS-R pain intensity scores from time 0 through 24 hours The subject was to rest for at least 5 minutes before responding to the following question, "On a scale of 0 to 10, where 0 = no pain and 10 = worst possible pain, how much pain are you having right now?"

Secondary Endpoints
Adverse Event Profile
30 days
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Sky0402EXPERIMENTALInjection of Study Drug
PlaceboPLACEBO_COMPARATORInjection of study drug
Interventions
NameTypeDescription
SKY0402DRUGLocal infiltration of 8cc SKY0402
PlaceboDRUGLocal infiltration of 8cc Placebo
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * Age ≥ 18 years at the Screening visit * Scheduled to undergo primary unilateral first metatarsal osteotomy without hammertoe * Female subjects must be surgically sterile or at least two years menopausal, or using an acceptable method of birth control. If of childbearing potent...

Countries:United States
Unlock Eligibility Criteria